Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-12-11
2007-12-11
Swope, Sheridan (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C435S193000
Reexamination Certificate
active
09937946
ABSTRACT:
A method for treating cerebral vascular diseases in a human or non-human animal is disclosed. The method involves inhibiting 20-HETE synthesizing enzyme activity sufficiently to increase or prevent a decrease in cerebral blood flow in the human or non-human animal.
REFERENCES:
patent: WO 99/43310 (1999-09-01), None
patent: WO9943310 (1999-09-01), None
patent: WO 01/32164 (2001-10-01), None
del Zoppo et al Clinical trials in acute stroke: why have they not been successful? Neurology. Sep 1998;51(3 Suppl 3):S59-61. Review.
Fotherby et al Stroke, blood pressure and antihypertensive therapy. J Hum Hypertens. Oct. 1997;11(10):625-7. Review.
Frisbee et al Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. Am J Physiol Heart Circ Physiol. May 2000;278(5):H1517-26.
Kalaria et al Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res. Nov. 12, 1998;62(1):101-5.
Schmidt et al Vascular risk factors in dementia. J Neurol. Feb. 2000;247(2):81-7. Review.
Su et al Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol. Aug 1998;275(2 Pt 2):R426-38.
Zhang et al Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. Trends Cardiovasc Med. Feb. 2002;12(2):62-6. Review.
Hoagland et al., Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension. Oct. 2003;42(4):669-73. Epub Jul. 21, 2003.
Lasker et al., Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem. Feb. 11, 2000;275(6):4118-26.
Alonso-Galicia, M. et al., “Inhibition of 20-HETE Production Contributes to the Vascular Responses to Nitric Oxide,” Hypertension 29:320-325 (1997).
Alonso-Galicia, M., et al., “Contribution of 20-HETE to Vasodilator Actions of Nitric Oxide in the Cerebral Microcirculation,” Stroke 30:2727-2734 (1999).
Alonso-Galicia, M., et al., “20-HETE agonists and antagonists in the renal circulation,”Am. J. Physiol.277:F790-F796 (1999).
Amet, Y., et al., “Cytochrome P450 4A and 2E1 Expression in Human Kidney Microsomes,”Biochemical Pharmacology53:765-771 (1997).
Amet, Y., et al., “Noninvolvement of CYP2E1 in the (ω-1)-hydroxylation of Fatty Acids in Rat Kidney Microsomes,”Biochemical Pharmacology54:947-952 (1997).
Amet, Y., et al., “P-450-Dependent Metabolism of Lauric Acid in Alcoholic Liver Disease: Comparison Between Rat Liver and Kidney Microsomes,”Alcoholism: Clinical and Experimental Research22:455-462 (1998).
Bednar, M.M., et al., “1 6(R)-Hydroxy-5,8,11,14-eicosatetraenoic Acid, a New Arachidonate Metabolite in Human Polymorphonuclear Leukocytes,”Biochemical Pharmacology60:447-455 (2000).
Christmas, P., et al., “Alternative Splicing Determines the Function of CYP4F3 by Switching Substrate Specificity,”Journal of Biological Chemistry276:38166-38172 (2001).
Clozel, M. et al., “BQ-123, A Peptidic Endothelin ETAReceptor Antagonist, Prevents the Early Cerebral Vasospasm Following Subarachnoid Hemorrhage After Intracisternal But Not Intravenous Injection,”Life Sciences52:825-834 (1993).
Croft, K., et al., “Angiotensin II releases 20-HETE from rat renal microvessels,”Am. J. Physiol. Renal Physiol.279:F544-F551 (2000).
Dahly, A.J., et al., “Chronic Anti-TGF-β Therapy Improves Blood Pressure and Renal Function in Dahl S Rats,”FASEB J.14:A133 (2000).
Dahly, A.J., et al. “Chronic Anti-TGF-β Ab Therapy Reduces Proteinuria and Renal Injury in Hypertensive Rats,”American Society of Hephrology Renal Week1 1:332A (2000).
Gebremedhin, D., et al., “Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+current,”Journal of Physiology507.3:771-781 (1998).
Gebremedhin, D., et al., “Production of 20-HETE and Its Role in Autoregulation of Cerebral Blood Flow,”Circulation Research87:60-65 (2000).
Harder, D.R., et al., “Formation and action of aP-450 4A metabolite of arachidonic acid in cat cerebral microvessels,”American Physiological Society266:H2098-H2107 (1994).
Juvela S., “Plasma endothelin concentrations after aneurysmal subarchnoid hemorrhage,”J. Neurosurg.92:390-400 (2000).
Oyekan, A., et al., “Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II,”American Physiological Society273:R293-R300 (1997).
Powell, P.K., et al., “Metabolism of Arachidonic Acid to 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid by P450 Enzymes in Human Liver:Involvement of CYP4F2 and CYP4A11,”Journal of Pharmacology and Experimental Therapeutics285:1327-1336 (1998).
Rosolowsky, M., “Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites,”Biochimica et Biophysica Acta1300:143-150 (1996).
Seifert, V., et al., “Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage,”J. Neurosurg.82:55-62 (1995).
Wang, M., et al., “Contribution of cytochromeP-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys,”American Physiological Society276L:F246-F253 (1999).
Wang, M., et al., “Cytochrome P450-Derived Arachidonic Acid Metabolism in the Rat Kidney:Characterization of Selective Inhibitors,”The Journal of Pharmacology and Experimental Therapeutics284:966-973 (1998).
Zou, A., et al., “Effects of 17-Octadecynoic Acid, a Suicide-Substrate Inhibitor of Cytochrome P450 Fatty Acid ω-Hydroxylase, on Renal Function in Rats,”The Journal of Pharmacology and Experimental Therapeutics268:474-481 (1994).
Lange, et al., 20-Hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J Biol Chem. Oct. 24, 1997;272(43):27345-52.
Zou, et al., Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol. Feb. 1994;266(No. 2 Pt 2):F275-82.
Miyata, et al., HET006, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol. Jun. 2001;133(3):325-9.
Harder David R.
Kameo Kazuya
Miyata Noriyuki
Okuyama Shigeru
Roman Richard J.
MCW Research Foundation, Inc.
Quarles & Brady LLP
Swope Sheridan
Taisho Pharmaceutical Co. Ltd.
LandOfFree
Use of 20-HETE synthesizing enzyme inhibitors as therapy for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 20-HETE synthesizing enzyme inhibitors as therapy for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 20-HETE synthesizing enzyme inhibitors as therapy for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3853831